---
title: "Mounjaro (tirzepatide) in type 2 diabetes: Safety questions"
description: "Safety questions on Mounjaro (tirzepatide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects. Questions: What are the long-term side effects of Mounjaro over 104 weeks (SURPASS-EARLY)? What are the most common side effects of Mounjaro? Mounjaro nausea and stomach side effects: how common are they? Do Mounjaro stomach side effects like nausea go away over time? 5 further questions follow. 9 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Mounjaro (tirzepatide) in type 2 diabetes: Safety questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Mounjaro](https://uspl.lilly.com/mounjaro/mounjaro.html#pi)

Safety questions that apply to every indication of Mounjaro are on [Mounjaro (tirzepatide), all indications: Safety](https://www.evicenter.com/medical-information/mounjaro/safety).

## Side effects

<a id="mounjaro-surpass-early-safety"></a>

### What are the long-term side effects of Mounjaro over 104 weeks (SURPASS-EARLY)?

Applies to: Adults with type 2 diabetes diagnosed within 0 to 4 years and inadequately controlled on metformin alone (SURPASS-EARLY)

> “SURPASS-EARLY was a randomized, open-label, parallel-group, phase 4 study to evaluate the long-term efficacy and safety of Mounjaro 15 mg or MTD + metformin compared with ICC + metformin in 794 adults diagnosed with type 2 diabetes within 0-4 years, whose blood glucose was inadequately controlled with diet and exercise and metformin (≥1500 mg/day or maximum tolerated dose for at least 90 days before baseline), alone. Metformin was to be continued as background therapy.<sup>3</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=SURPASS%2DEARLY%20was%20a%20randomized%2C%20open%2Dlabel%2C,to%20be%20continued%20as%20background)

> “Common adverse events and incidence of hypoglycemia in patients taking Mounjaro 15 mg or MTD vs ICC through 104 weeks<sup>3</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Common%20adverse%20events%20and%20incidence,MTD%20vs%20ICC%20through%20104)

> “For Mounjaro 15 mg or MTD plus metformin and ICC plus metformin, respectively: nausea 22.7% and 17.5%; diarrhea 21.9% and 13.4%; dyspepsia 17.1% and 6.3%; constipation 14.4% and 11.6%; vomiting 13.9% and 10.4%; eructation 6.8% and 1.5%; decreased appetite 5.5% and 3.5%; headache 5.5% and 3.0%; influenza 4.5% and 5.8% and nasopharyngitis 2.5% and 5.3%”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=For%20Mounjaro%2015%20mg%20or,and%20nasopharyngitis%202.5%25%20and%205.3%25)

On the page, select: Table Description

> “A table that shows the incidence of hypoglycemia for patients taking Mounjaro 15 mg or maximum tolerated dose plus metformin (n=397) and intensified conventional care plus metformin (n=395). Incidence of severe hypoglycemia in both treatment groups was 0%. Incidence of blood glucose less than 54 mg/dL was 17 patients (4.3%) in the Mounjaro 15 mg or maximum tolerated dose group and 13 patients (3.3%) in the intensified conventional care plus metformin group.”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=A%20table%20that%20shows%20the,conventional%20care%20plus%20metformin%20group.)

On the page, select: Table Description

> “<sup>a</sup>Severe hypoglycemia defined as episodes requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.<sup>2</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=hypoglycemia%20defined%20as%20episodes%20requiring,carbohydrate%2C%20glucagon%2C%20or%20other%20resuscitative)

Note: The adverse event values are from the table description on the clinical data page, whose opening sentence describes the hypoglycemia table; the values match the visible Common Adverse Events Occurring in ≥5% of Patients table. Each percentage is the incidence of the event through week 104. SURPASS-EARLY is not described in the Prescribing Information.

<a id="mounjaro-side-effects"></a>

### What are the most common side effects of Mounjaro?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “Table 1 shows common adverse reactions, not including hypoglycemia, associated with the use of MOUNJARO in the pool of placebo-controlled trials in adults. These adverse reactions occurred more commonly on MOUNJARO than on placebo and occurred in at least 5% of patients treated with MOUNJARO.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Table%201%20shows%20common%20adverse,of%20patients%20treated%20with%20MOUNJARO.)

> “Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials Reported in ≥5% of MOUNJARO-treated Adult Patients with Type 2 Diabetes Mellitus
>
> Note: Percentages reflect the number of patients who reported at least 1 occurrence of the adverse reaction.
>
>
> Adverse Reaction	Placebo
> (N=235)
> %	MOUNJARO
> 5 mg
> (N=237)
> %	MOUNJARO
> 10 mg
> (N=240)
> %	MOUNJARO
> 15 mg
> (N=241)
> %
> Nausea	4	12	15	18
> Diarrhea	9	12	13	17
> Decreased Appetite	1	5	10	11
> Vomiting	2	5	5	9
> Constipation	1	6	6	7
> Dyspepsia	3	8	8	5
> Abdominal Pain	4	6	5	5”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Table%201%3A%20Adverse%20Reactions%20in,5)

> “The data in Table 1 are derived from 2 placebo-controlled trials [1 monotherapy trial (SURPASS-1) and 1 trial in combination with basal insulin with or without metformin (SURPASS-5)] in adult patients with type 2 diabetes mellitus [see Clinical Studies (14.2, 14.4)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=The%20data%20in%20Table%201,%5Bsee%20Clinical%20Studies%20%2814.2%2C%2014.4%29%5D.)

> “In the pool of seven clinical trials in adults, the types and frequency of common adverse reactions, not including hypoglycemia, were similar to those listed in Table 1.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=In%20the%20pool%20of%20seven,those%20listed%20in%20Table%201.)

Note: Table 1 columns are placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order (% of patients).

<a id="mounjaro-gi-side-effects"></a>

### Mounjaro nausea and stomach side effects: how common are they?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In the pool of placebo-controlled trials in adults, gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO than placebo (placebo 20.4%, MOUNJARO 5 mg 37.1%, MOUNJARO 10 mg 39.6%, MOUNJARO 15 mg 43.6%). More patients receiving MOUNJARO 5 mg (3.0%), MOUNJARO 10 mg (5.4%), and MOUNJARO 15 mg (6.6%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%).”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=In%20the%20pool%20of%20placebo%2Dcontrolled%20trials%20in%20adults%2C%20gastrointestinal,than%20patients%20receiving%20placebo%20%280.4%25%29.)

> “The following gastrointestinal adverse reactions were reported more frequently in MOUNJARO-treated adult patients than placebo-treated patients (frequencies listed, respectively, as: placebo; 5 mg; 10 mg; 15 mg): eructation (0.4%, 3.0%, 2.5%, 3.3%), flatulence (0%, 1.3%, 2.5%, 2.9%), gastroesophageal reflux disease (0.4%, 1.7%, 2.5%, 1.7%), abdominal distension (0.4%, 0.4%, 2.9%, 0.8%).”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=The%20following%20gastrointestinal%20adverse%20reactions,distension%20%280.4%25%2C%200.4%25%2C%202.9%25%2C%200.8%25%29.)

<a id="mounjaro-gi-side-effects-duration"></a>

### Do Mounjaro stomach side effects like nausea go away over time?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=The%20majority%20of%20reports%20of,escalation%20and%20decreased%20over%20time.)

<a id="mounjaro-manage-gi-side-effects"></a>

### How can Mounjaro nausea and stomach side effects be reduced?

> “Follow the starting dosage recommendation and dosage escalation schedule below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Follow%20the%20starting%20dosage%20recommendation,%285.6%29%20and%20Adverse%20Reactions%20%286.1%29%5D.)

> “Daniel Nadeau, MD: First of all, when starting Mounjaro, it is important to follow the recommended dosage escalation to reduce the risk of gastrointestinal adverse reactions.
>
> In addition, I would advise patients to eat smaller more frequent meals, for example, splitting 3 daily meals into 4 smaller meals, and to stop eating when they feel full.
>
> Eating bland foods like toast or crackers, and avoiding fatty foods may also help with nausea.”

Source: [MOUNJARO: PEDs, captured 2026-11-12](https://mounjaro.lilly.com/hcp/peds#:~:text=Daniel%20Nadeau%2C%20MD%3A%20First%20of,may%20also%20help%20with%20nausea.)

On the page, select: Video transcript

> “Inform patients of the potential risk of severe gastrointestinal adverse reactions. Instruct patients to contact their healthcare provider if they have severe or persistent gastrointestinal symptoms [see Warnings and Precautions (5.6)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Inform%20patients%20of%20the%20potential%20risk%20of%20severe,%5Bsee%20Warnings%20and%20Precautions%20%285.6%29%5D.)

Note: The eating suggestions are an endocrinologist's counseling advice for pediatric patients in the SURPASS-PEDS video on the pediatric page of the Mounjaro HCP site; they do not appear in the Prescribing Information.

<a id="mounjaro-hypoglycemia"></a>

### Does Mounjaro cause low blood sugar, especially with insulin or a sulfonylurea?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “Patients receiving MOUNJARO in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions (6.1), Drug Interactions (7.1)].
>
> The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Patients%20receiving%20MOUNJARO%20in%20combination,signs%20and%20symptoms%20of%20hypoglycemia.)

> “Table 2: Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Adult Patients with Type 2 Diabetes Mellitus
>
> Note: Percentages reflect the number of patients who reported at least 1 episode of hypoglycemia in respective categories.
>
>
>
>
> * Reflects the study treatment period. Data include events occurring during 4 weeks of treatment-free safety follow up. Events after introduction of a new glucose-lowering treatment are excluded.
>
>
>
>
> ** Episodes requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.
>
>
>
> 	Placebo
>
> %	MOUNJARO
> 5 mg
> %	MOUNJARO
> 10 mg
> %	MOUNJARO
> 15 mg
> %
> Monotherapy				
>       (40 weeks)*	N=115	N=121	N=119	N=120
>      Blood glucose <54 mg/dL	1	0	0	0
>      Severe hypoglycemia**	0	0	0	0
> Add-on to Basal Insulin with or without Metformin				
>       (40 weeks)*	N=120	N=116	N=119	N=120
>      Blood glucose <54 mg/dL	13	16	19	14
>      Severe hypoglycemia**	0	0	2	1”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Table%202%3A%20Hypoglycemia%20Adverse%20Reactions,1)

> “Hypoglycemia was more frequent when MOUNJARO was used in combination with a sulfonylurea [see Clinical Studies (14)]. In an adult clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level <54 mg/dL) occurred in 13.8%, 9.9%, and 12.8%, and severe hypoglycemia occurred in 0.5%, 0%, and 0.6% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Hypoglycemia%20was%20more%20frequent%20when,mg%2C%20and%2015%20mg%2C%20respectively.)

> “When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=When%20initiating%20MOUNJARO%2C%20consider%20reducing,%5Bsee%20Warnings%20and%20Precautions%20%285.3%29%5D.)

Note: Table 2 columns are placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order.

<a id="mounjaro-peds-side-effects"></a>

### What are the side effects of Mounjaro in children?

Applies to: Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus

> “The incidences of adverse reactions reported in pediatric patients treated with MOUNJARO 5 mg and 10 mg subcutaneously once-weekly were consistent with those described above for adult patients with type 2 diabetes mellitus with the exception of a higher incidence of vomiting, abdominal pain, and hypoglycemia. During the 30-week placebo-controlled period of the study, vomiting occurred in 3%, 16%, and 12% of patients and abdominal pain occurred in 9%, 22%, and 15% of patients treated with placebo, MOUNJARO 5 mg, and 10 mg, respectively.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=The%20incidences%20of%20adverse%20reactions,mg%2C%20and%2010%20mg%2C%20respectively.)

> “No severe hypoglycemia episodes were reported during the trial in pediatric patients 10 years of age and older with type 2 diabetes mellitus. Table 3 summarizes the incidence of hypoglycemic events with blood glucose <54 mg/dL in this trial.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=No%20severe%20hypoglycemia%20episodes%20were,%3C54%20mg%2FdL%20in%20this%20trial.)

> “Table 3: Hypoglycemia Adverse Reactions in the 30 Week Trial of MOUNJARO Added to Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus
>
> Note: Percentages reflect the number of patients who reported at least 1 episode of blood glucose <54 mg/dL.
>
>
>
>
> a Events after the introduction of a new glucose-lowering treatment are excluded.
>
>
> 	Placebo
> %	MOUNJARO
> 5 mg
> %	MOUNJARO
> 10 mg
> %
> Add on to basal insulin with or without metformina	N=10	N=10	N=11
>      Blood glucose <54 mg/dL	10	30	27
> Add on to metformin alonea	N=24	N=22	N=22
>      Blood glucose <54 mg/dL	4	9	9”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Table%203%3A%20Hypoglycemia%20Adverse%20Reactions,9)

> “A table that shows the adverse events in pediatric patients in the Mounjaro 5 mg (n=32), Mounjaro 10 mg (n=33), pooled Mounjaro (5 mg and 10 mg) (n=65), or placebo (n=34) groups. Percentages reflect the number of patients who reported at least 1 occurrence of the adverse event in the Mounjaro 5 mg group, Mounjaro 10 mg group, pooled Mounjaro (5 mg and 10 mg) group, and placebo group, respectively. Diarrhea: 8 (25%), 8 (24%), 16 (25%), and 2 (6%). Nausea: 7 (22%), 6 (18%), 13 (20%), and 3 (9%). Vomiting: 5 (16%), 4 (12%), 9 (14%), and 1 (3%). Upper abdominal pain: 2 (6%), 4 (12%), 6 (9%), and 3 (9%). Abdominal pain: 5 (16%), 1 (3%), 6 (9%), and 1 (3%). Dyspepsia: 2 (6%), 4 (12%), 6 (9%), and 0. Headache: 2 (6%), 3 (9%), 5 (8%), and 1 (3%). Oropharyngeal pain: 3 (9%), 1 (3%), 4 (6%), and 2 (6%). Cough: 3 (9%), 1 (3%), 4 (6%), and 1 (3%). Hyperglycemia: 0, 0, 0, and 5 (15%). Nasopharyngitis: 1 (3%), 2 (6%), 3 (5%), and 2 (6%). Decreased appetite: 0, 4 (12%), 4 (6%), and 0. Anxiety: 1 (3%), 2 (6%), 3 (5%), and 0. Gastroenteritis: 0, 0, 0, and 2 (6%). Injection site reaction: 0, 2 (6%), 2 (3%), and 0. Tonsillitis: 2 (6%), 0, 2 (3%), and 0.”

Source: [MOUNJARO: PEDs, captured 2026-11-12](https://mounjaro.lilly.com/hcp/peds#:~:text=A%20table%20that%20shows%20the,0%2C%202%20%283%25%29%2C%20and%200.)

On the page, select: Table description

Note: Table 3 columns are placebo, MOUNJARO 5 mg, and 10 mg, in that order. The visible SURPASS-PEDS adverse events table on the pediatric page labels the pooled group n=33 and gives pooled vomiting as 13 (20%) and placebo vomiting as 3 (9%); its table description gives n=65, 9 (14%), and 1 (3%). The label combines abdominal pain and upper abdominal pain, which the site lists separately.

<a id="mounjaro-injection-site-reactions"></a>

### How common are injection site reactions with Mounjaro?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In the pool of placebo-controlled trials in adults, injection site reactions were reported in 3.2% of MOUNJARO-treated patients compared to 0.4% of placebo-treated patients.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=In%20the%20pool%20of%20placebo%2Dcontrolled%20trials%20in%20adults%2C%20injection,to%200.4%25%20of%20placebo%2Dtreated%20patients.)

<a id="mounjaro-heart-rate"></a>

### Does Mounjaro increase heart rate?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In the pool of placebo-controlled trials in adults, treatment with MOUNJARO resulted in a mean increase in heart rate of 2 to 4 beats per minute compared to a mean increase of 1 beat per minute in placebo-treated patients. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of ≥15 beats per minute, also were reported in 4.3%, 4.6%, 5.9% and 10% of subjects treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. For patients enrolled in Japan, these episodes were reported in 7% (3/43), 7.1% (3/42), 9.3% (4/43), and 23% (10/43) of patients treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. The clinical relevance of heart rate increases is uncertain.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=In%20the%20pool%20of%20placebo%2Dcontrolled%20trials%20in%20adults%2C%20treatment,heart%20rate%20increases%20is%20uncertain.)

## Related pages
- [Medical information: Mounjaro (tirzepatide): Type 2 diabetes](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes)
- [Indication](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/access-and-coverage)
